RCC and other tumors in von Hippel-Lindau syndrome patients are outliers in that disease progression is often associated with loss of HIF-1α expression, which may be due in part to selection against HIF-1α–dependent inhibition of MYC activity (168). The gene discussed is HIF1A; the disease is renal cell carcinoma.